


In Re Application of: Ziva MESSIKA et al

Application No.: 09/445,105

Filed: March 7, 2000

For: PREPARATION OF GLYCOSYLATED TUMOR PROLIFERATION FACTOR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Art Unit: 1647

Examiner: J. Seharaseyon

Washington, D.C.

Atty.'s Docket: MESSIKA=1

Date: January 29, 2002

GAU 1647
RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a ☒ Amendment ☒ Combined Declaration Signed by Inventor Ze'Evi
in the above-identified application.

☐ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

☐ No additional fee is required.

☒ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 12	MINUS	** 20		0
INDEP.	* 4	MINUS	*** 4		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	
\$	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	
\$	

OR

OR

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
Response Filed Within
☐ First - \$ 55.00
☐ Second - \$ 200.00
☐ Third - \$ 460.00
☐ Fourth - \$ 720.00
Month After Time Period Set

Other Than Small Entity
Response Filed Within
☐ First - \$ 110.00
☒ Second - \$ 400.00
☐ Third - \$ 920.00
☐ Fourth - \$ 1440.00
Month After Time Period Set

☐ Less fees (\$) already paid for month(s) extension of time on .

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$.

☒ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ 400.00.

☐ A check in the amount of \$ is attached (check no.).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By:
Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197



#9/B
RECEIVED
Dmt
FEB 04 2002
1-29-02
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: MESSIKA=1

In re Application of:)	Conf. No.:
)	
Ziva MESSIKA et al)	Art Unit: 1647
)	
Appln. No.: 09/445,105)	Examiner: J. Seharaseyon
)	
Filed: March 7, 2000)	Washington, D.C.
)	
For: PREPARATION OF)	January 29, 2002
GLYCOSYLATED TUMOR)	
NECROSIS FACTOR)	

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of August 29, 2001,
petition for a two-month extension of time and payment being
attached hereto, please amend as follows:

IN THE CLAIMS

Please rewrite claims 1, 2, 5 and 6 in amended form
as follows:

B1 *[Signature]*
1 (Amended). Isolated glycosylated human tumor
necrosis factor having cytotoxic biological activity.

B2 *[Signature]*
2 (Twice-amended). A method for preparing isolated
glycosylated human tumor necrosis factor exhibiting cytotoxic
biological activity, comprising:

(a) ligating DNA encoding human TNF, or a mutant
thereof exhibiting cytotoxic biological activity, which mutant